He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Apollo continues to invest in genomics technology and research for better patient care
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Subscribe To Our Newsletter & Stay Updated
